ArticleNature communications2020
Identification of osteogenic progenitor cell-targeted peptides that augment bone formation.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Metallic Contaminants and Osteoporosis: a Review of the Gut-Bone Axis.Biological trace element research · 2026Review
- Beyond resorption-driven coupling: a multi-layered framework for osteoclast-osteoblast communication and its therapeutic consequences.Frontiers in endocrinology · 2026Review
- Article
- Microbial Influences on Calcium-Phosphorus Homeostasis and Metabolic Bone Diseases: A Bidirectional Mendelian Randomisation Study on the Gut-Bone Axis.Journal of cellular and molecular medicine · 2025Article
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- The Role of microRNA in the Regulation of Differentiation and the Functionality of Osteoblasts, Osteoclasts, and Their Precursors in Osteoporosis.Non-coding RNA · 2025Review
- Spatiotemporal application of small molecules in fracture healing.Biomaterials translational · 2025Review
- My Perspective on OBOC Combinatorial Technology.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Beyond linearity: a threshold effect links serum creatinine to SIRI in osteoporotic fractures.Frontiers in medicine · 2025Article
- Functional mechanism and clinical implications of LINC00339 in delayed fracture healing.Journal of orthopaedic surgery and research · 2024Article
- diABZI and poly(I:C) inhibit osteoclastic bone resorption by inducing IRF7 and IFIT3.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024Article
- High-precision bioactive scaffold with dECM and extracellular vesicles targeting 4E-BP inhibition for cartilage injury repair.Materials today. Bio · 2024Article
- Evaluating the association between lifestyle factors and heel bone mineral density in different inflammatory states.Heliyon · 2024Article
- Biomaterial design for regenerating aged bone: materiobiological advances and paradigmatic shifts.National science review · 2024Review
- Microbiota-bone axis in ageing-related bone diseases.Frontiers in endocrinology · 2024Review
- Unraveling the potential mechanisms of the anti-osteoporotic effects of theFrontiers in pharmacology · 2023Article
- More than skin deep: cyclic peptides as wound healing and cytoprotective compounds.Frontiers in cell and developmental biology · 2023Review
- Metabolic Bone Diseases and New Drug Developments.Biomolecules & therapeutics · 2022Review
- Generation of functional oligopeptides that promote osteogenesis based on unsupervised deep learning of protein IDRs.Bone research · 2022Article
- Recombinant Limb Assay asFrontiers in cell and developmental biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Activation and migration of endogenous mesenchymal stromal cells (MSCs) are critical for bone regeneration. Here, we report a combinational peptide screening strategy for rapid discovery of ligands that not only bind strongly to osteogenic progenitor cells (OPCs) but also stimulate osteogenic cell Akt signaling in those OPCs. Two lead compounds are discovered, YLL3 and YLL8, both of which increase osteoprogenitor osteogenic differentiation in vitro. When given to normal or osteopenic mice, the compounds increase mineral apposition rate, bone formation, bone mass, and bone strength, as well as expedite fracture repair through stimulated endogenous osteogenesis. When covalently conjugated to alendronate, YLLs acquire an additional function resulting in a "tri-functional" compound that: (i) binds to OPCs, (ii) targets bone, and (iii) induces "pro-survival" signal. These bone-targeted, osteogenic peptides are well suited for current tissue-specific therapeutic paradigms to augment the endogenous osteogenic cells for bone regeneration and the treatment of bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.